Skogen Vegard, Helleren Rita, Jacobsen Marianne Giske, Opsal Anne, Gallefoss Frode
Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, PO Box 6050 Langnes, Tromsø N-9037, Norway.
Department of Infectious Diseases, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
JAC Antimicrob Resist. 2024 Oct 14;6(5):dlae155. doi: 10.1093/jacamr/dlae155. eCollection 2024 Oct.
Outpatient parenteral antimicrobial therapy (OPAT) is safe, effective and increasingly available. While OPAT in Norwegian healthcare has been rare, a new continuous ambulatory delivery device (CADD) allowing multiple daily dosing treatments has been innovated making OPAT more accessible.
To describe the clinical outcome and safety using CADD in an OPAT setting.
Adult patients in need of parenteral antibiotic treatment were offered OPAT and discharged with a programmable digital infusion pump allowing multiple daily dosings.
Altogether, 170 patients were included in the study, among which 21% of all patients (36 of 170) were readmitted to hospital while receiving OPAT or within 30 days after end of intravenous antibiotics. None of the 170 patients died due to OPAT and allergies were not noticeable as a problem.
We have developed a safe and clinically effective programme offering OPAT in accordance with Norwegian antibiotic treatment guidelines.
门诊胃肠外抗菌治疗（OPAT）安全、有效且应用日益广泛。虽然在挪威医疗保健中OPAT很少见，但一种新型连续非卧床给药装置（CADD）已被研发出来，它能实现每日多次给药治疗，使OPAT更容易获得。
描述在门诊胃肠外抗菌治疗（OPAT）环境中使用连续非卧床给药装置（CADD）的临床结果和安全性。
需要胃肠外抗生素治疗的成年患者接受门诊胃肠外抗菌治疗（OPAT），并使用可编程数字输液泵出院，该输液泵可实现每日多次给药。
该研究共纳入170例患者，其中21%（170例中的36例）的患者在接受门诊胃肠外抗菌治疗（OPAT）期间或静脉使用抗生素结束后30天内再次入院。170例患者中无一人因门诊胃肠外抗菌治疗（OPAT）死亡，且未发现过敏问题。
我们依据挪威抗生素治疗指南制定了一个安全且临床有效的门诊胃肠外抗菌治疗（OPAT）方案。
